Cargando…

Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market

BACKGROUND: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shabaninejad, Hosein, Mehralian, Gholamhossein, Rashidian, Arash, Baratimarnani, Ahmad, Rasekh, Hamid Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234990/
https://www.ncbi.nlm.nih.gov/pubmed/24708770
http://dx.doi.org/10.1186/2008-2231-22-35
_version_ 1782344945115332608
author Shabaninejad, Hosein
Mehralian, Gholamhossein
Rashidian, Arash
Baratimarnani, Ahmad
Rasekh, Hamid Reza
author_facet Shabaninejad, Hosein
Mehralian, Gholamhossein
Rashidian, Arash
Baratimarnani, Ahmad
Rasekh, Hamid Reza
author_sort Shabaninejad, Hosein
collection PubMed
description BACKGROUND: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies’ competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). RESULTS: The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area. CONCLUSION: This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets’ needs.
format Online
Article
Text
id pubmed-4234990
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42349902014-11-19 Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market Shabaninejad, Hosein Mehralian, Gholamhossein Rashidian, Arash Baratimarnani, Ahmad Rasekh, Hamid Reza Daru Research Article BACKGROUND: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies’ competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). RESULTS: The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area. CONCLUSION: This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets’ needs. BioMed Central 2014-04-03 /pmc/articles/PMC4234990/ /pubmed/24708770 http://dx.doi.org/10.1186/2008-2231-22-35 Text en Copyright © 2014 Shabaninejad et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Shabaninejad, Hosein
Mehralian, Gholamhossein
Rashidian, Arash
Baratimarnani, Ahmad
Rasekh, Hamid Reza
Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
title Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
title_full Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
title_fullStr Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
title_full_unstemmed Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
title_short Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
title_sort identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234990/
https://www.ncbi.nlm.nih.gov/pubmed/24708770
http://dx.doi.org/10.1186/2008-2231-22-35
work_keys_str_mv AT shabaninejadhosein identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket
AT mehraliangholamhossein identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket
AT rashidianarash identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket
AT baratimarnaniahmad identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket
AT rasekhhamidreza identifyingandprioritizingindustrylevelcompetitivenessfactorsevidencefrompharmaceuticalmarket